Table 1 Characteristics of the included studies
From: The association of HBV infection and head and neck cancer: a systematic review and meta-analysis
First Author, Year | Country | Year of enrolment | Control group/ Cohort population | Event of control group | Number of control group | Cancer site | Event of case group | Number of case group | HBV marker |
|---|---|---|---|---|---|---|---|---|---|
Case-control studies (n = 10) | |||||||||
Takata, 2002 [12] | Kitakyushu, Japan | 1989–1998 | impacted teeth | 3 | 350 | 442 oral cavity | 5 | 442 | HBsAg |
Ye, 2015 [9] | Guangzhou, China | 2008/1-2013/5 | healthy population | 97 | 680 | 711 nasopharynx | 112 | 711 | HBsAg |
Wei, 2017 [10] | Guangzhou, China | 2008–2014 | cancer free patients | 723 | 5715 | 4152 nasopharynx | 791 | 4152 | HBsAg |
Kocoglu, 2018 [13] | Istanbul, Turkey | 2000–2014 | healthy volunteers | 3168 | 96,000 | 204 head and neck | 12 | 204 | HBsAg |
An, 2018 [21] | Seoul, South Korea | 2007–2014 | cancer-free controls | 4401 | 118,891 | 1750 head and neck | 95 | 1750 | HBsAg |
Lu, 2018 [11] | Guangzhou, China | 2007–2016 | residents in South China | 14,823 | 169,211 | 3323 nasopharynx | 535 | 3323 | HbsAg |
Mahale, 2019 [17] | Maryland, USA | 1993–2013 | cancer-free population | 966 | 200,000 | 4417 salivary glands/14,479 oral cavity/8515 oropharynx/12,334 larynx/4141 other head and neck sites(1165 nasopharynx/2251 hypopharynx) | - | - | ICD-9 |
Donà , 2019 [14] | Treviso, Italy | 2000–2018 | cancer free patients | 26 | 1518 | 107 oral cavity/202 oropharynx/83 hypopharynx/382 larynx | 35 | 774 | HBsAg |
Komori, 2020 [15] | Okayama, Japan | 2008–2017 | non-HNC patient | 5 | 495 | 512 head and neck(152 oral cavity/10 nasopharynx/57 oropharynx/120 hypopharynx/80 larynx/26 salivary glands/67 others) | 5 | 512 | HBsAg + HBcAb |
Tian, 2020 [16] | Nanjing, China | 2008–2016 | cancer-free subjects | 625 | 11,361 | 378 oral cavity/82 nasopharynx/82 hypopharynx/345 larynx | 80 | 887 | HBV sero-markers |
Cohort studies | |||||||||
Kamiza, 2016 [19] | Taiwan, China | 2000–2005 | healthy population | 233 | 63,552 | 47 head and neck | 47 | 12,369 | ICD-9-CM |
Song, 2019 [20] | Nanjing, China | 2004/6-2008/7 | healthy population | 395 | 481,377 | 20 oral cavity | 20 | 15,355 | HBsAg |
Hong, 2020 [22] | Seoul, South Korea | 2003–2013 | no HBV or HCV population | 638 | 500,680 | 32 head and neck(3 larynx) | 32 | 26,665 | ICD-10 |